Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Anika Therapeutics Inc. (ANIK : NSDQ)
 
 • Company Description   
Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Number of Employees: 297

 
 • Price / Volume Information   
Yesterday's Closing Price: $20.98 Daily Weekly Monthly
20 Day Moving Average: 113,084 shares
Shares Outstanding: 14.54 (millions)
Market Capitalization: $305.13 (millions)
Beta: 1.11
52 Week High: $48.37
52 Week Low: $19.95
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.71% 3.24%
12 Week -34.70% -26.61%
Year To Date -41.45% -28.47%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
32 WIGGINS AVENUE
-
BEDFORD,MA 01730
USA
ph: 781-457-9000
fax: 781-305-9720
investorrelations@anika.com http://www.anikatherapeutics.com
 
 • General Corporate Information   
Officers
Cheryl R. Blanchard - Chief Executive Officer and President
Jeffery S. Thompson - Chairman
Michael Levitz - Chief Financial Officer; Executive Vice President
Ian McLeod - Vice President and Chief Accounting Officer
Sheryl L. Conley - Director

Peer Information
Anika Therapeutics Inc. (CORR.)
Anika Therapeutics Inc. (RSPI)
Anika Therapeutics Inc. (CGXP)
Anika Therapeutics Inc. (BGEN)
Anika Therapeutics Inc. (GTBP)
Anika Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 035255108
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 14.54
Most Recent Split Date: (:1)
Beta: 1.11
Market Capitalization: $305.13 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.55 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.07
Price/Cash Flow: 14.84
Price / Sales: 2.03
EPS Growth
vs. Year Ago Period: -283.33%
vs. Previous Quarter: 52.17%
Sales Growth
vs. Year Ago Period: 7.00%
vs. Previous Quarter: 2.43%
ROE
03/31/22 - -0.92
12/31/21 - -0.11
09/30/21 - 1.63
ROA
03/31/22 - -0.75
12/31/21 - -0.08
09/30/21 - 1.27
Current Ratio
03/31/22 - 6.12
12/31/21 - 5.66
09/30/21 - 5.76
Quick Ratio
03/31/22 - 4.82
12/31/21 - 4.45
09/30/21 - 4.54
Operating Margin
03/31/22 - -1.76
12/31/21 - -0.20
09/30/21 - 3.16
Net Margin
03/31/22 - -1.09
12/31/21 - 2.80
09/30/21 - -3.96
Pre-Tax Margin
03/31/22 - -1.66
12/31/21 - 1.64
09/30/21 - -4.52
Book Value
03/31/22 - 19.65
12/31/21 - 19.89
09/30/21 - 20.09
Inventory Turnover
03/31/22 - 1.78
12/31/21 - 1.66
09/30/21 - 1.51
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©